Johnson & Johnson (JNJ) subsidiary Janssen Pharmaceuticals says the FDA has approved...

Johnson & Johnson (JNJ) subsidiary Janssen Pharmaceuticals says the FDA has approved Xarelto, an oral anticoagulant for the treatment of deep vein thrombosis and/or pulmonary embolism. The drug has a broad reimbursement base, encompassing more than 90% of commercial and Medicare health plan members.

From other sites
Comments (2)
  • snowr
    , contributor
    Comments (2) | Send Message
    i have had a pulmonary embolism and recently a blood clot in my leg. My MD wanted to replace warfarin with this drug, but was waiting to see if it was approved by FDA . this is good news.
    3 Nov 2012, 01:02 AM Reply Like
  • fish4uinmd
    , contributor
    Comments (298) | Send Message
    I had a total hip replacement last year...wish it had been available then. Yet another reason to own this innovative company...there R&D is one of the best in the business...hopefully it will save lives.
    3 Nov 2012, 06:30 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs